Earlier this week Celine Halioua (ODF2), founder and CEO of Loyal — a dog longevity biotech startup — announced something truly groundbreaking.
Loyal (ODF2) has earned what they believe to be the FDA’s first-ever formal acceptance that a drug can be developed and approved for lifespan extension.
As Celine says in her announcement; “I started Loyal 4 years ago with the explicit goal to get the first drug FDA approved for lifespan extension itself - no disease, just healthy, longer"..."We can't start selling the drug yet - we need to complete the safety and manufacturing technical sections - but this represents the lions share of the 'existential risk' of both the drug program, and of Loyal AKA - we are doing it!!!”
Laura Deming is a longevity biotech investor with an incredible batting average. 5 of 18 startups she’s backed so far have gone public. She was the first investor in Loyal and had this to say:
"This just dropped - the most important milestone in the history of longevity biotech. put simply, this is the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. the longevity field is evolving quickly. No one I know in the field would have said this was possible 5 years ago. Celine got it done in 4. It’s a massive win for both biotech founders and regulators, in establishing a pathway by which drugs (initially for dogs) can get approved for lifespan"
You’re about to listen to an archival interview with Celine just one and a half years into starting Loyal which is now 4 years old. It’s an incredible conversation with interviewer Marshall Kosloff and shows just how much can be accomplished in a few short years.
Congrats to Celine and the entire Loyal team on what is truly an unparalleled milestone.
Are you exploring starting a company we’ve got a program for that?
ODF has helped 1k companies like Loyal which was ODF2 get started and go on to raise over $2B. Applications for our 20th cohort in San Francisco are now . Learn more and apply at beondeck.com
Deep Dive: Find the right co-founder and idea with Mo El Mahallawy, CTO and co-founder of Shepherd
Deep Dive: Shutting down a startup, doing right by your team, and founder identity with Stevie Cline (VC at Vol. 1 Ventures)
Control Your Financial Destiny: Runway, Metrics, and more with Puzzle's CEO Sasha Orloff
Augmenting people with AI and building the future featuring Matt Rastovac of Respell
Defense Tech: Opportunities to support America and our allies with veteran Mike Slagh (founder/CEO of Shift)
Lessons from the Journey to Building a Product Customers Want with Max Greenwald of Warmly
Generative AI and deciding what to build first with Elaine Zelby of Tofu
Explore Starting a Company in San Francisco
Raising $40M to Build Health Insurance for India with Amrit Singh
Combating the Autoimmune Epidemic with Wallace Torres
Raising $175M to Translate Nature Into Medicine with Viswa Colluru
Intro: How to Help People Live Longer and Healthier Lives
AI Companionship with Replika's Eugenia Kuyda
Fundraising and Venture Capital in 2023 with Julian Weisser
From Personal Health Transformation to Magic AI with Varun Bhanot
Raising from Sam Altman to Build Land Valuation Models with Will Jarvis
Navigating the Idea Maze to Reinvent Children Education with Ryan Delk
Raising $2.2M to Make Home Ownership Flexible with Lauren Self
Housing and Regulation with Kim-Mai Cutler from Initialized
Create your
podcast in
minutes
It is Free
Insight Story: Tech Trends Unpacked
Zero-Shot
Fast Forward by Tomorrow Unlocked: Tech past, tech future
The Unbelivable Truth - Series 1 - 26 including specials and pilot
Acquired